References in periodicals archive ?
(NASDAQ: RVNC) has completed patient enrollment in two pivotal trials of the company's SAKURA Phase 3 programme for its investigational drug candidate DaxibotulinumtoxinA for Injection (RT002) for the treatment of moderate to severe glabellar lines in adults, the company said.
The analyst points out that shares of Revance (RVNC), which also competes with Allergan in the botulinum toxin space, dropped yesterday as well.
Revance (RVNC) downgraded to Market Perform from Outperform at JMP Securities with analyst Donald Ellis citing Botox study data released by Allergan (AGN).
He believes the Allergan pursuit is not a risk for Revance (RVNC), but is actually confirming of the latter company's thesis that there is indeed a viable market for longer-acting toxins.
Among the notable losers was Revance Therapeutics (RVNC), which dropped 10% after Lauren Silvernail resigned as Revance's CFO and Chief Business Officer to become CFO at competitor Evolus (EOLS).
After Evolus (EOLS) announced that it hired Lauren Silvernail, formerly the CFO at Revance Therapeutics (RVNC), to be its own CFO, JMP Securities analyst Donald Ellis noted this was the second hiring by the company of a C-suite executive from a major competitor after the company had previously hired CEO David Moatazedi from Allergan (AGN).
The potential launches of Evolus' (EOLS) DWP-450 in 2018 and Revance Therapeutics' (RVNC) RT002 in 2020 has investors wondering if less expensive and longer lasting toxins could take meaningful share away from Allergan's (AGN) Botox, Cantor Fitzgerald analyst Louise Chen tells investors in a research note.
Shares of Allergan (AGN) are under pressure this morning after Mylan (MYL) and Revance Therapeutics (RVNC) announced an agreement for the development and commercialization of a proposed biosimilar to Botox.
The collaboration between Revance (RVNC) and Mylan (MYL) to develop a biosimilar Botox does not help sentiment on Allergan (AGN) shares, JPMorgan analyst Chris Schott tells investors in a research note.
Mylan (MYL) and Revance Therapeutics (RVNC) announced a global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX, the "market-leading neuromodulator approved for the treatment of multiple indications and usage in the United States with additional approvals globally." Mylan said: "The addition of this product further solidifies Mylan's long term commitment to the development and commercialization of biosimilars and complex products globally." The companies plan to work together to gain regulatory approval in the development of this important biosimilar product, and commercialize this product in the U.S., Europe and applicable markets throughout the rest of the world.
After competitor Revance Therapeutics' (RVNC) announced positive clinical results from two Phase 3 studies for its new drug RT002 to potentially treat frown lines, a spokesperson for Allergan (AGN) told The Fly: "While there are currently other neurotoxin products in development, and others having been approved and available on the market for many years, the clinical profile and market leadership of BOTOX and BOTOX Cosmetic are well established.
Wells Fargo analyst David Maris views the selloff today in shares of Allergan (AGN) following Revance Therapeutics' (RVNC) frown lines data as overdone.
Acronyms browser ?
Full browser ?